Adult Vaccines Market Forecast Reveals Where Future Industry Value Will Be Created
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Adult Vaccines Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The adult vaccines sector has experienced robust expansion in recent years, with projections indicating an increase from $24.21 billion in 2025 to $26.34 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. Historically, this growth has been driven by factors such as a higher incidence of infectious diseases, implementation of government-led vaccination programs, creation of innovative vaccine formulations, a growing elderly demographic, and enhancements in healthcare facilities.
The adult vaccines market is projected to experience robust expansion in the coming years, with its value anticipated to reach $37.51 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.2%. This forecast period growth is fueled by progress in mRNA and recombinant vaccine technologies, greater funding for adult immunization initiatives, improved cold chain infrastructure, heightened consciousness about vaccine-preventable illnesses, and strategic partnerships between pharmaceutical and biotech firms. Key developments shaping this period encompass a surge in adult vaccination education, broader rollout of immunization programs, creation of combination vaccines, an uptick in vaccines targeting chronic disease management, and increased requirements for travel and occupational vaccines.
Download A Free Sample Report For Comprehensive Market Insights:
Adult Vaccines Market Expansion Drivers: What Is Shaping Future Growth?
The expansion of the adult vaccine market was fueled by rising healthcare spending. Healthcare expenditure encompasses the total expenses associated with delivering healthcare services to a population. When healthcare spending increases, it typically results in more investment in medical research and development. By funding vaccination initiatives and improving vaccine accessibility, healthcare systems can diminish the prevalence of preventable diseases and enhance overall community health. Moreover, adult immunization can generate substantial cost efficiencies by lowering healthcare usage and the necessity for costly medical interventions. For example, as reported in November 2023 by the Canadian Institute for Health Information, a health organization based in Canada, the nation’s total healthcare expenditure for 2023 is anticipated to be $344 billion—an increase of more than $9 billion from 2022. Consequently, the rise in healthcare spending had a favorable effect on the development of the adult vaccine market.
Adult Vaccines Market Segment Landscape: Which Areas Lead Market Development?
The adult vaccines market covered in this report is segmented –
1) By Vaccine Type: Monovalent, Multivalent
2) By Technology: Live Attenuated Vaccines, Inactivated Viral Or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines
3) By Application: Influenza, DPT, Human Papillomavirus, Zoster, Pneumococcal, Hepatitis
4) By End Users: Healthcare Firms, Hospitals
Subsegments:
1) By Monovalent: Single Antigen Vaccines, Specific Disease Vaccines
2) By Multivalent: Combination Vaccines, Multi-Antigen Vaccines
Adult Vaccines Market Strategic Trends: What Is Defining The Next Phase Of Growth?
In the adult vaccines market, major players are actively focusing on technological innovation, particularly the development of mRNA-based vaccines designed to generate rapid and precise immune responses, addressing the growing demand for adult immunization against respiratory illnesses. This type of vaccine utilizes messenger RNA enclosed in lipid nanoparticles, which instructs human cells to produce specific viral proteins and subsequently trigger an immune reaction without relying on a live or attenuated virus. As an example, in May 2024, the U.S.-based biotechnology firm Moderna obtained FDA approval for mRESVIA, an mRNA-based vaccine targeting respiratory syncytial virus (RSV), intended for adults aged 60 and older. This vaccine encodes the prefusion F glycoprotein of RSV and is supplied in single-dose, pre-filled syringes, facilitating the production of neutralizing antibodies, enhancing both safety and efficacy relative to conventional inactivated or live-attenuated vaccines, and broadening the range of adult immunization options available.
Adult Vaccines Market Industry Leaders And Market Competition
Major companies operating in the adult vaccines market are GlaxoSmithKline PLC, Merck & Co, Sanofi Pasteur, Pfizer Inc, Commonwealth Serum Laboratories Limited, Johnson & Johnson, Serum Institute of India, AstraZeneca PLC, Novartis AG, Protein Sciences Corporation, Emergent BioSolutions Inc., Bavarian Nordic A/S, Dynavax Technologies Corporation, Novavax Inc, Medimmune LLC, BioNTech SE, Moderna, Inovio Pharmaceuticals, Sinovac, Valneva Se, Biological E Limited, Panacea Biotec, Shenzhen Kangtai Biological Products, Beijing Tiantan Biological Products, Hualan Biological Engineering, Chengdu Institute of Biological Products, Bharat Biotech International Limited, Takeda Pharmaceutical Company Limited
Access The Complete Adult Vaccines Market Report:
Adult Vaccines Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the adult vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the adult vaccines market during the forecast period. The regions covered in the adult vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
